R&D oppotunity

SCOTLAND should capitalise on a gap in the market as big pharmaceutical companies scale back their research and development, according to the man charged with commercialising ideas from the Edinburgh BioQuarter.

Mike Capaldi said he aims to build on existing relationships with companies including Pfizer, GlaxoSmithKline and Toshiba in a bid to attract more companies to Scotland.

Edinburgh BioQuarter – which includes Scottish Enterprise, Edinburgh University, NHS Lothian and Alexandria Real Estates Equities – aims to create 6,500 jobs and attract 250 million of investment to Scotland over the next 15 years.